Biodexa Pharmaceticals (BDRX) — Cash Flow-to-Debt Ratio
Biodexa Pharmaceticals (BDRX) has a Cash Flow-to-Debt Ratio of -0.34x as of December 2025, meaning its operating cash flow of $-2.33 Million could theoretically repay 0% of its total liabilities ($6.76 Million) in one year. Explore BDRX cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Biodexa Pharmaceticals Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Biodexa Pharmaceticals across 14 annual periods. Also explore Biodexa Pharmaceticals asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Biodexa Pharmaceticals (2012–2025)
Year-by-year debt coverage analysis for Biodexa Pharmaceticals. For market capitalisation and broader financial context, see BDRX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.80x | $-5.39 Million | $6.76 Million | ▲ +58.0% |
| 2024 | -1.90x | $-12.26 Million | $6.46 Million | ▼ -63.1% |
| 2023 | -1.16x | $-6.83 Million | $5.86 Million | ▲ +61.0% |
| 2022 | -2.98x | $-7.05 Million | $2.36 Million | ▼ -22.2% |
| 2021 | -2.44x | $-6.01 Million | $2.46 Million | ▲ +18.6% |
| 2020 | -3.00x | $-9.30 Million | $3.10 Million | ▼ -424.4% |
| 2019 | -0.57x | $-6.49 Million | $11.34 Million | ▲ +85.0% |
| 2018 | -3.82x | $-13.45 Million | $3.52 Million | ▼ -329.2% |
| 2017 | -0.89x | $-12.95 Million | $14.55 Million | ▲ +25.4% |
| 2016 | -1.19x | $-13.09 Million | $10.96 Million | ▼ -64.8% |
| 2015 | -0.72x | $-12.42 Million | $17.15 Million | ▲ +38.0% |
| 2014 | -1.17x | $-5.46 Million | $4.67 Million | ▼ -16.1% |
| 2013 | -1.00x | $-4.44 Million | $4.41 Million | ▼ -271.4% |
| 2012 | -0.27x | $-3.22 Million | $11.89 Million | — |